Eli Lilly Stock Finishes Lower After News of Bond Sale to Fund Morphic Deal

By Yahoo! Finance | Aug 13, 2024 at 04:23 AM EST

Deutsche Bank analysts upgraded Eli Lilly's stock to a buy rating after a strong quarterly report. Despite a dip due to $5 billion bond sales news, the company's shares rose by nearly 15%, reaching above $904. The acquisition of Morphic and promising drug developments influenced the upgrade.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.